The purpose of the study is to determine if administering a low dose of Tranexamic Acid shortly after the baby is delivered can reduce the need for a blood transfusion before the mother is discharged from the hospital. Participants in the study will receive either Tranexamic Acid or a placebo through an injection shortly after their cesarean delivery. The study will monitor the amount of blood loss and whether a blood transfusion is needed, as well as any side effects that may occur. The trial will also look at other factors such as the mother’s recovery and overall health after delivery.

Throughout the study, participants will be observed for any potential side effects of Tranexamic Acid, such as nausea or dizziness, and for any serious complications like blood clots. The study will also assess the mother’s satisfaction with her delivery experience and her psychological well-being after childbirth. The trial aims to provide valuable information on whether Tranexamic Acid can be a safe and effective way to manage blood loss in women with placenta previa undergoing cesarean delivery.

The purpose of the study is to determine if progesterone can help prevent preterm births in women with placenta previa. Participants in the study will receive progesterone treatment, while others will not receive any treatment, allowing researchers to compare the outcomes. The study will monitor various factors, including the rate of preterm births before 37 weeks of pregnancy, the duration of pregnancy, and any side effects experienced by the mothers. The study will also look at the health of the newborns, including their birth weight and any need for special care after birth.

Throughout the study, participants will be closely monitored to ensure their safety and the health of their babies. The trial aims to provide valuable insights into whether progesterone can be an effective treatment for preventing preterm births in women with placenta previa, potentially improving outcomes for both mothers and their babies.